Immediate Impact

8 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 Standout
CAR T-cell therapy in autoimmune diseases
2023 Standout
2 intermediate papers

Works of Lawrence D. Durack being referenced

High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
2004
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
1999

Author Peers

Author Last Decade Papers Cites
Lawrence D. Durack 745 709 238 441 18 1.2k
Christopher C. Badger 947 449 225 365 25 1.3k
Mars B. van ’t Veer 241 524 193 350 36 1.4k
Judith Estes 934 880 334 455 10 1.4k
Leslie E. Botnick 194 593 150 483 31 1.6k
Denise Regan 1165 925 388 469 13 1.6k
Mehmet F. Fer 394 313 126 404 22 1.1k
Christine De Wolf‐Peeters 501 855 360 387 11 1.2k
SA Rosenberg 225 751 362 587 28 1.7k
Max S. Topp 285 471 141 779 35 1.2k
Martina Chiarucci 279 1232 218 890 10 1.7k

All Works

Loading papers...

Rankless by CCL
2026